Your Genes Determine How Your Body Processes CBD — and Its Side Effects
A clinical study found that genetic variations in liver enzymes significantly affect CBD blood levels and side effects, with certain gene combinations causing 5x more diarrhea — paving the way for personalized CBD dosing.
Quick Facts
What This Study Found
CYP2C19 metabolizer status significantly affected CBD exposure, with lower CBD levels in intermediate metabolizers (p=0.014 single dose, p=0.003 steady state). Individuals with both CYP3A5 poor metabolism and CYP2C19 intermediate/normal metabolism had increased active metabolite exposure and experienced diarrhea 5.6x more frequently (39% vs. 7%, p=0.046).
Key Numbers
33 healthy subjects. CBD 5mg/kg single dose then 5mg/kg BID x14 days. Diarrhea: 39% in CYP3A5 poor + CYP2C19 intermediate/normal vs. 7% others (p=.046). CYP2C19 intermediate metabolizers: lower CBD exposure (p=.014 single, p=.003 steady state). External cohort validated CYP2C19 findings.
How They Did This
Secondary analysis of open-label, fixed-sequence, single-center study. 33 healthy subjects received single-dose CBD 5mg/kg then titrated to 5mg/kg twice daily for 14 days. CYP3A, CYP2C9, and CYP2C19 genotypes assessed. Pharmacokinetic parameters by noncompartmental analysis. External validation cohort confirmed CYP2C19 findings.
Why This Research Matters
With millions using CBD products, understanding why some people experience side effects while others don't is crucial. This study shows genetics play a major role — opening the door to pharmacogenomic-guided CBD dosing and better prediction of drug interactions.
The Bigger Picture
This is the beginning of personalized cannabinoid medicine. Just as genetic testing guides dosing for drugs like warfarin and clopidogrel, CBD dosing may eventually be tailored to an individual's genetic profile to maximize benefit and minimize side effects.
What This Study Doesn't Tell Us
Small sample (33 subjects). Healthy volunteers may differ from patients. Single formulation and dosing regimen. Not all CYP genotype combinations well-represented. Open-label design.
Questions This Raises
- ?Should genetic testing be recommended before high-dose CBD use?
- ?Would genotype-guided dosing reduce side effects in epilepsy patients on Epidiolex?
- ?Can pharmacogenomics predict CBD-drug interactions?
Trust & Context
- Key Stat:
- Evidence Grade:
- Small but well-designed pharmacogenomic study with external validation — strong mechanistic evidence though clinical application needs larger trials.
- Study Age:
- Published in 2026, advancing pharmacogenomic understanding of CBD metabolism.
- Original Title:
- Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers.
- Published In:
- Clinical and translational science, 19(1), e70455 (2026)
- Authors:
- Etkins, Jumar, So, Gerald C, Lu, Jessica Bo Li, Koyama, Sachiko, Gisch, Debora L, Melo Ferreira, Ricardo, Cheng, Ying-Hua, McClara, Kelsey, Jun, Joshua, Miller, Matthew, Desta, Zeruesenay, Eadon, Michael T
- Database ID:
- RTHC-08259
Evidence Hierarchy
Frequently Asked Questions
Why do some people get side effects from CBD and others don't?
This study found genetics play a major role. Variations in liver enzymes (CYP3A5, CYP2C19) affect how your body processes CBD and its metabolites. Certain gene combinations led to 5.6x more diarrhea, explaining why CBD tolerance varies so much between people.
Should I get genetic testing before using CBD?
Not yet standard practice, but this study suggests it could become valuable — especially for people on high-dose prescription CBD (Epidiolex) or those taking multiple medications that use the same liver enzymes.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-08259APA
Etkins, Jumar; So, Gerald C; Lu, Jessica Bo Li; Koyama, Sachiko; Gisch, Debora L; Melo Ferreira, Ricardo; Cheng, Ying-Hua; McClara, Kelsey; Jun, Joshua; Miller, Matthew; Desta, Zeruesenay; Eadon, Michael T. (2026). Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers.. Clinical and translational science, 19(1), e70455. https://doi.org/10.1111/cts.70455
MLA
Etkins, Jumar, et al. "Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers.." Clinical and translational science, 2026. https://doi.org/10.1111/cts.70455
RethinkTHC
RethinkTHC Research Database. "Genotype-Specific Safety and Pharmacokinetics of Cannabidiol..." RTHC-08259. Retrieved from https://rethinkthc.com/research/etkins-2026-genotypespecific-safety-and-pharmacokinetics
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.